Torsemide Extended-Release Tablet for Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diuretic therapies for congestive heart failure (CHF) face challenges such as short duration of action, unpredictable effects, and adverse side effects due to rapid plasma concentration fluctuations, leading to compromised therapeutic efficacy and increased healthcare costs.
Innovation Solution
Development of an extended-release oral dosage formulation of Torsemide using a matrix component like hydroxypropyl methyl cellulose (HPMC) or glyceryl behenate, which maintains steady plasma levels and prolongs diuresis and natriuresis, reducing side effects and improving patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional immediate-release diuretic formulations are used, then rapid diuretic action is achieved, but duration of action is short (2-4 hours)
Solution Approach 1:
The patent segments the diuretic dose into multiple smaller doses delivered at different times through a multi-layered tablet structure. Each layer contains a portion of the total dose and releases it at a different rate, thereby extending the duration of action while maintaining rapid initial onset from the first layer
Solution Approach 2:
The patent implements periodic action by designing the tablet to release the diuretic in multiple distinct phases or bursts over time. The controlled-release mechanism creates periodic elevation of plasma concentration, maintaining therapeutic effect throughout the day without requiring continuous high dosing
2Duration of action of moving object
If high doses of diuretics are administered to extend duration, then duration of action increases, but plasma concentration fluctuations become more extreme
Solution Approach 1:
By dividing the total daily dose into multiple smaller segments delivered throughout the day via the multi-layered tablet, the patent avoids the need for a single large dose. This segmentation smooths plasma concentration fluctuations while extending duration of action
Solution Approach 2:
The patent achieves continuity of useful action by ensuring steady, controlled release of the diuretic throughout the day. The multi-layered design maintains therapeutic plasma concentrations continuously, eliminating the peaks and troughs associated with conventional dosing
3Duration of action of moving object
If multiple daily doses are administered, then duration of coverage is improved, but patient compliance decreases
Solution Approach 1:
The patent merges multiple individual doses into a single multi-layered tablet that delivers the entire daily regimen in one administration. This combining of multiple dosing events into one physical unit dramatically improves patient compliance while maintaining extended duration of action through the controlled-release mechanism
4Ease of manufacture
If conventional diuretic formulations are used, then manufacturing simplicity is maintained, but therapeutic efficacy is compromised
Solution Approach 1:
The patent employs composite materials by combining multiple layers with different release characteristics within a single tablet. This composite structure enables complex therapeutic profiles (rapid onset plus extended duration) while remaining manufacturable using conventional tabletting techniques applied to layered formulations
Data Source
AI summary
Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.